Waaxda Caalamiga ah

CT011 waa barnaamij isku-dhafan oo loogu talagalay daaweynta kansarka beerka ee unugyada (HCC). CT011 waxay ka heshay NMPA ogolaansho IND sanadkii 2019 si loogu daaweeyo bukaanada qaba burooyinka adag ee GPC3-positive kaas oo ahaa oggolaanshihii ugu horreeyay ee IND ee Shiinaha ee daaweynta unugyada CAR ee ka dhanka ah ...Akhriso wax dheeraad ah»

Bare jaamacadeed oo Ruush ah oo da'diisu tahay toddobaatanaadkii ayaa la ildaran cudurka myeloma-da badan ee horumarsan. Ka dib markii uu qaatay daawayn badan iyo laba jeer oo uu ku soo noq noqday tallaalkii autologous, wuxuu ka bartay daaweynta kansarka ee ugu casrisan ee CAR-T ee Shiinaha, sidaas darteed wuxuu u yimid Shiinaha si uu u helo unugyada CAR-T ee...Akhriso wax dheeraad ah»

Luulyo 20, Codsiga Daawada Cusub (NDA) ee pCAR-19B oo si madax-bannaan loo sameeyay oo ay samaysay Precision Biology waxaa si rasmi ah u aqbalay Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha (NMPA). Badeecadani waa badeecaddii ugu horreysay ee CAR-T ee loogu talagalay leukemia carruurnimada ee Shiinaha, taas oo loo isticmaalo in lagu daaweeyo bukaannada da'doodu u dhaxayso 3-21 ...Akhriso wax dheeraad ah»

satricabtagene autoleucel（Satri-cel,CT041) waa musharax isku-dhafan oo CAR T-cell ah oo ka soo horjeeda borotiinka Claudin18.2 kaasoo leh awood uu ku noqdo heerka koowaad ee adduunka. Satri-cel wuxuu bartilmaameedsadaa burooyinka adag ee Claudin18.2 oo diiradda saaraya kansarka caloosha/cancer-ka isku xirka caloosha iyo mindhicirka...Akhriso wax dheeraad ah»

Sebtembar 6, 2021, JW Therapeutics waxay ku dhawaaqday in Maamulka Badeecadaha Caafimaadka Qaranka (NMPA) ee Shiinaha uu ansixiyay Codsiga Daawada Cusub (NDA) ee ka hortagga CD19 autologous chimeric antigen receptor T (CAR-T) ee wax soo saarka difaaca jirka ee relmacabtagene autoleucel irbadda (relma-cel) ...Akhriso wax dheeraad ah»

Equecabtagene autoleucel (eque-cel), oo ah daaweyn unugyada T-cell-ka ah oo si buuxda uga soo jeeda bini'aadamka oo ay soo saarto B-cell bislaanshaha antigen-bartilmaameedsan ee chimeric antigen receptor (CAR), ayaa muujisay awood ay ku daweyn karto myeloma badan oo soo noqnoqda ama aan la qabsan karin (R/RMM). Juun 30, 2023, Badeecadaha Caafimaadka Qaranka ee Shiinaha ayaa...Akhriso wax dheeraad ah»

Oktoobar 11, 2024, Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha (NMPA) ayaa ansixiyay codsiga Daawada Cusub ee Baaritaanka (IND) ee loogu talagalay Inaticabtagene Autoleucel (CNCT19 Duritaanka), oo ah daaweyn unugyada difaaca jirka ee loo yaqaan 'chimeric antigen receptor (CAR)-T cell' oo CD19-ku beegsanayo, si loogu daaweeyo xinjirowga dhiigga ee difaaca jirka ...Akhriso wax dheeraad ah»

Maarso 1, 2024, Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha (NMPA) ayaa ansixiyay soo bandhigidda badeecada unugyada CAR-T ee Zevorcabtagene AutoLeucel (Zevor-cel, CT053) si loogu daaweeyo bukaanada qaangaarka ah ee qaba myeloma badan oo soo noqnoqda ama aan firfircoonayn kuwaas oo horumar sameeyay ka dib ugu yaraan 3 saf oo daaweyn ah (...Akhriso wax dheeraad ah»